Yahoo · Oct 23, 2026
Argenx's Vyvgart Sales Growth, Pipeline Progress Support Outlook, Oppenheimer Says
Argenx's (ARGX) Q3 results highlighted continued growth in Vyvgart sales, while its acquisition of F
AR
NASDAQ · ARGX
argenx SE
Healthcare · Biotechnology
$892.87
Down-$4.98 (-0.55%)
Updated Oct 31, 2026, 5:02 PM
SID Score
5.5/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 47.46B
- P/E ratio
- 42.26
- Dividend yield
- 0.00%
- 52-week range
- $661.85 – $1,072.75
- Volume
- 462.45K
- Avg. volume
- 347.54K
Price performance · ARGX
ARGX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ARGX closed at $892.87 after 21 trading sessions, down 2.87% for the selected period.
- Last close
- $892.87
- Period change
- -2.87%
- Period low
- $802.64
- Period high
- $930.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $896.79 | $916.05 | $890.01 | $892.87 | 462.45K |
| Oct 29, 2026 | $898.98 | $907.25 | $894.41 | $897.85 | 160.89K |
| Oct 28, 2026 | $873.08 | $897.03 | $870.21 | $891.76 | 193.37K |
| Oct 27, 2026 | $864.81 | $882.60 | $859.32 | $882.48 | 290.15K |
| Oct 26, 2026 | $876.46 | $884.18 | $864.11 | $869.33 | 269.57K |
| Oct 23, 2026 | $875.98 | $887.07 | $865.715 | $873.705 | 298.97K |
| Oct 22, 2026 | $853.28 | $897.27 | $853.28 | $875.76 | 1.02M |
| Oct 21, 2026 | $875.27 | $892.85 | $873.225 | $890.05 | 656.69K |
| Oct 20, 2026 | $847.53 | $881.10 | $843.51 | $869.72 | 536.45K |
| Oct 19, 2026 | $815.555 | $828.69 | $814.405 | $825.61 | 394.79K |
| Oct 16, 2026 | $842.80 | $843.61 | $813.05 | $819.14 | 389.02K |
| Oct 15, 2026 | $842.46 | $858.21 | $838.78 | $846.27 | 510.77K |
| Oct 14, 2026 | $809.03 | $835.31 | $803.00 | $818.30 | 464.12K |
| Oct 13, 2026 | $817.165 | $822.2825 | $798.48 | $802.64 | 277.15K |
| Oct 12, 2026 | $832.33 | $832.49 | $810.70 | $812.30 | 241.2K |
| Oct 9, 2026 | $821.955 | $826.78 | $805.07 | $825.03 | 512.25K |
| Oct 8, 2026 | $831.23 | $832.24 | $787.73 | $818.63 | 2.45M |
| Oct 7, 2026 | $932.08 | $942.685 | $921.72 | $928.44 | 258.33K |
| Oct 6, 2026 | $922.39 | $942.35 | $909.945 | $930.52 | 430.07K |
| Oct 5, 2026 | $920.825 | $923.31 | $903.50 | $912.87 | 322.13K |
| Oct 2, 2026 | $926.86 | $928.96 | $912.96 | $919.21 | 333.88K |
Latest ARGX news
The latest Smart Investors Daily articles mentioning ARGX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ARGX research
Overview
Company profile and research snapshot.
Company profile
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $967.36
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Sep 22, 2026 | BNP PARIBAS | Outperform | — |
| Sep 22, 2026 | TD COWEN | Buy | — |
| Sep 21, 2026 | DAY BY DAY | Buy | — |
| Sep 14, 2026 | KBC SECURITIES | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 23, 2026
Argenx's Vyvgart Beats Expectations With Focus Shifting to December Data, RBC Says
Argenx's (ARGX) Vyvgart sales beat expectations in Q3, with investors focused on upcoming multifocal
Benzinga · Oct 23, 2026
Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1190
Morgan Stanley analyst Sean Laaman maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1140 to $1190.
Yahoo · Oct 23, 2026
argenx: 3 Key Takeaways for Long-Term Investors
Pipeline expansion into new indications could sustain growth long after VYVGART matures, a rare diversification for a single-drug biotech.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
